Table 1.

Study population

	No relapse (N = 15)	Relapse/flare-up (N = 3)	Discontinued therapy (N = 9)
Age, years median (range)	32.0 (10.0–60.0)	18.0 (18.0–30.0)	25 (13.0–47.0)
Sex ratio, M:F	14:1	2:1	7:2
Lesion type
Polymorphic	13	3	8
Macular	2	0	1
Interval between cure of VL and onset of PKDL (median years, range)	1.0 (0.6–42.0)	10.0 (1.0–40.0)	3.0 (0.75–10.0)
Disease duration from onset of PKDL till receiving treatment for PKDL (median years, range)	6.0 (0.5–21.0)	7.0 (2.0–11.0)	2.5 (0.25–11.0)
Treatment with miltefosine
4 weeks	0	0	9§
12 weeks	4	3‡	0
16 weeks	11	0	0
Follow-up period (median months, range)	63.0 (41.0–78.0)*	17.0 (17.0–39.0)†	Not applicable

PKDL = Post-kala-azar dermal leishmaniasis; VL = visceral leishmaniasis.

^*Disease-free period.

^†Lag period between stoppage of treatment and relapse/flare-up.

^‡Therapy stopped because of cerebrovascular accident (N = 1) or severe abdominal pain/vomiting (N = 2).

^§Declined therapy due to severe abdominal pain/vomiting.